Rozanolixizumab is unique in that it is the only FDA approved treatment for both AchR and MuSK autoantibody (+) MG and works by reducing total IgG levels, including IgG4. MuSK (+) MG is mostly a pathogenic IgG4-mediated disorder with direct inhibition of protein interactions and damage of the post-...
I tend to use rozanolixizumab in a few different situations for MuSK myasthenia. The obvious one is when patients have a significant bulbar weakness that needs to be controlled ASAP. Aside from that, I may try rozanolixizumab in patients who do not respond well to prednisone, primarily to get them b...
It is a first-line drug for me for MG due to MuSK ab, as the MycarinG trial showed a benefit, and it has an indication from the FDA for this condition.